Highly Uniform Spherical MoO2-MoO3/Polypyrrole Core-Shell Nanocomposite as an Optoelectronic Photodetector in UV, Vis, and IR Domains.

A highly uniform spherical MoO2-MoO3/polypyrrole core-shell nanocomposite has been successfully synthesized as an optoelectronic photon sensing material, capable of detecting light in the UV, Vis, and IR domains. The nanocomposite is prepared through the oxidation of pyrrole using Na2MoO4, resulting in a uniform spherical morphology that has been confirmed by TEM, theoretical modeling, and SEM analyses. This morphology contributes to its promising optical behavior, characterized by a small bandgap of 1.36 eV. The optoelectronic photosensing capability of the nanocomposite has been evaluated across the UV, Vis, and IR spectra, demonstrating high efficiency. The photoresponsivity R values indicate the ability of the nanocomposite to generate hot electrons in response to incident photons. With an R value of 4.15 mA·W-1 at 440 nm, this optoelectronic device exhibits considerable promise for integration into an advanced technological apparatus. The detection (D) value of 9.30 × 108 Jones at 440 nm further confirms the high sensitivity in the Vis region. The excellent stability of the device can be attributed to the inherent MoO2-MoO3 oxide and Ppy polymer materials. This stability has been demonstrated through reproducibility studies and current-voltage measurements under various optical conditions. The combination of stability, efficiency, and sensitivity makes this optoelectronic device well suited for light sensing applications in both industrial and commercial settings. Its promising performance opens up opportunities for advancements in various fields requiring accurate and reliable light detection.

Highly Uniform Multi-Layers Reduced Graphene Oxide/Poly-2-aminobenzene-1-thiol Nanocomposite as a Promising Two Electrode Symmetric Supercapacitor under the Effect of Absence and Presence of Porous-Sphere Polypyrrole Nanomaterial.

A uniform and highly porous reduced graphene oxide/poly-2-aminobenzene-1-thiol multi-layer (R-GO/P2ABT-ML) nanocomposite was synthesized and characterized. The uniform layer structure and porosity of the nanocomposite, combined with its conductivity, make it an ideal candidate for use as a pseudo supercapacitor. To enhance the capacitance behavior, a porous ball structure polypyrrole (PB-Ppy) was incorporated into the nanocomposite. When tested at 0.2 A/g, the capacitance values of the R-GO/P2ABT-ML and R-GO/P2ABT-ML/PB-Ppy were found to be 19.6 F/g and 92 F/g, respectively, indicating a significant increase in capacitance due to the addition of PB-Ppy. The energy density was also found to increase from 1.18 Wh.kg-1 for R-GO/P2ABT-ML to 5.43 Wh.kg-1 for R-GO/P2ABT-ML/PB-Ppy. The stability of the supercapacitor was found to be significantly enhanced by the addition of PB-Ppy. The retention coefficients at 100 and 500 charge cycles for R-GO/P2ABT-ML/PB-Ppy were 95.6% and 85.0%, respectively, compared to 89% and 71% for R-GO/P2ABT-ML without PB-Ppy. Given the low cost, mass production capability, and easy fabrication process of this pseudo capacitor, it holds great potential for commercial applications. Therefore, a prototype of this supercapacitor can be expected to be synthesized soon.

Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.

BACKGROUND: Adiposity and non-alcoholic fatty liver disease (NAFLD) are common characteristics of metabolic syndrome (MS). Understanding the underlying pathogenesis is crucial for the development of new remedies. Resveratrol controls obesity and glycemic disorders in patients with MS. OBJECTIVES: This study aimed to evaluate the effect of resveratrol and dulaglutide on adipose tissues and liver in rats with MS, declaring their possible mechanisms. METHODS: Rats allocated as Control, MS (induced by a high fat/ high sucrose diet for eight weeks), MS + Resveratrol (30 mg/kg/day orally), and MS + Dulaglutide (0.6 mg/kg twice weekly SC); drugs administration was in the last four weeks. Serum biochemical measurements were done. Liver and visceral fat were processed for biochemistry, histopathology, and immunohistochemistry. RESULTS: MS results demonstrated significantly increased systolic and diastolic blood pressure, anthropometric measurements, serum levels of alanine aminotransferase (ALT), glycemic indices, and lipids with decreased HDL-C. Tissue levels of leptin, malondialdehyde (MDA), and TNF-α reactivity significantly increased. Expression of adiponectin, PPARγ, and insulin growth factor-1 (IGF-1) decreased. Also, Western blotting mRNA gene expression of liver SIRT-1 was down-regulated. Resveratrol and dulaglutide significantly and effectively reversed MS complexity, ameliorating all findings, particularly NAFLD and adiposity-induced inflammation. Resveratrol significantly appears superior to dulaglutide regarding the effects on hemodynamics, lipids, adipokines, IGF-1 levels, and adipocyte size. Parallel, dulaglutide has more influence on glycemic control. CONCLUSION: Protective effects of the drugs may be through correlations between SIRT-1/adipokines/IGF-1 and PPARγ, improving the cross-talk between insulin resistance, obesity markers, liver dysfunction, and TNF-α. Promising multi-beneficial therapies of resveratrol or dulaglutide in MS are recommended clinically for this purpose. Showing the Experimental Design.

Evaluation of nootropic activity of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice through AMPK pathway and amelioration of hippocampal morphological alterations.

Cognitive impairments such as dementia are considered the biggest challenges for public health. Benzodiazepines are often prescribed for treatment of anxiety disorder but they are associated with elevated risk of dementia. The present study has been designed to evaluate the neuroprotective effect of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice. Piracetam was used as an established nootropic agent. Mice were divided into 8 groups, group1; control group which received normal saline. groups 2, 3 and 4 were received telmisartan 0.3 mg/kg/day, metformin 100 mg/kg/day and piracetam 200 mg/kg/day respectively. group 5; DZP group that injected with diazepam 2.5 mg/kg, groups 6, 7 and 8 were received diazepam 2.5 mg/kg + telmisartan 0.3 mg/kg/day, metformin 100 mg/kg/day and piracetam 200 mg/kg/day respectively. All drugs were administrated for 15 successive days. Cognitive skills of the animals were examined with Elevated plus maze and Passive Shock Avoidance tests. Investigations of oxidative stress markers were performed. Gene expression levels of TNF-α, NFκB, Caspase 3 and AMPK were analyzed using RT-PCR. Histological and immunohistochemical techniques were performed in hippocampus using H&E, cresyl violet stain, anti GFAP and anti COX-2 immunostain. The study revealed that administration of diazepam increased initial and retention transfer latency as well as it decreased step down latency that means it caused memory impairment. There was a significant increase in hippocampal expression levels of TNF-α, NFκB, and Caspase 3 and downregulation of AMPK expression levels associated with increased neurodegeneration, astrocytes activation and COX-2 immunohistochemical staining. This study indicates that diazepam caused a decline in cognitive function depending on hippocampal activity. Telmisartan, a common antihypertensive agent and metformin, a traditional antidiabetic drug improved this cognitive dysfunction through their anti-oxidant and anti-inflammatory effect as they decreased initial and retention transfer latency as well as it increased step down latency. Also they decreased TNF-α, NFκB, and Caspase 3 and upregulated AMPK expression, moreover they ameliorated the hippocampal morphological alterations, GFAP and COX-2 immunoexpression.